Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Renovacor, Inc. (CHAQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/01/2022 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Certificate of Formation of Zebrafish Merger Sub II, LLC",
"Limited Liability Company Agreement of Zebrafish Merger Sub II, LLC"
10/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation of Renovacor, Inc.",
"Presentation of Renovacor, Inc."
09/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation of Renovacor, Inc."
09/20/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Renovacor, Inc, Rocket Pharmaceuticals, Inc., Merger Sub I and Merger Sub II",
"Form of Voting and Support Agreement between Renovacor, Inc. and the stockholders party thereto",
"Form of Voting and Support Agreement between Rocket Pharmaceuticals, Inc. and the stockholders party thereto",
"Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy"
08/08/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between the Company and Frederick Driscoll, and effective as of March 28, 2022",
"Employment Agreement, by and between the Company and Frederick Driscoll, and effective as of March 28, 2022"
03/24/2022 8-K Quarterly results
Docs: "Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew Killeen, Ph.D., as CSO and Elizabeth White, Ph.D., as CBO and SVP of Operations Reported topline preclinical data demonstrating successful cardiac transduction with REN-001 delivered via local infusion at a low vector dose in a pilot pig study Significant progress made across key ongoing REN-001 IND-enabling studies IND submission for REN-001 is expected in the second half of 2022 with the initiation of a Phase I/II cli...",
"RENOVACOR CORPORATE PRESENTATION NYSE: RCOR"
03/02/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Renovacor, Inc. Consolidated Statements of Operations Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Operating expenses: Research and development $ 2,925 $ 892 $ 7,413 $ 1,868 General and administrative 2,315 147 3,227 547 Loss from operations Other income : Change in fair value of warrant liability — — Change in fair value of share earnout liability — — Other income , net — — Net Loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted-average number of common shares used in computing net loss per share applicable to common stockholders - basic and diluted 9,794,348 3,863,631 7,460,719 3,514,096 Renovacor, Inc. Consolidated Balance Sheet Data September 30, December 31, 2021 2020 Cash $ 85,321 $ 5,384 Other assets 2,655 108 Total assets $..."
11/02/2021 8-K Other Events  Interactive Data
Docs: "RENOVACOR COPORATE PRESENTATION NYSE: RCOR"
09/30/2021 8-K Quarterly results
09/09/2021 8-K Quarterly results
09/02/2021 8-K Quarterly results
08/03/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Chardan Healthcare Acquisition 2 Corp. Announces Record Date for Stockholders Eligible to Vote on Merger"
03/23/2021 8-K Quarterly results
06/09/2020 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
Docs: "Balance Sheet"
05/04/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Balance Sheet"
04/29/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Underwriting Agreement, by and between the Company and Chardan Capital Markets, LLC",
"Amended and Restated Certificate of Incorporation",
"Warrant Agreement, by and between Continental Stock Transfer & Trust Company and the Company",
"Letter Agreements, among the Registrant and the Company’ s officers, directors and Initial Stockholders",
"Investment Management Trust Agreement, by and between Continental Stock Transfer & Trust Company and the Company",
"Stock Escrow Agreement, among the Registrant, Continental Stock Transfer & Trust Company and the Initial Stockholders",
"Registration Rights Agreement, by and between the Registrant and Initial Stockholders",
"Promissory Note, by and between the Registrant and Chardan Investments 2, LLC",
"Indemnity Agreements, by and among the Registrant and the directors and officers of the Registrant",
"Subscription Agreement, by and between the Registrant and Chardan Investments 2, LLC"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy